Departments of1Neurosurgery.
4Center for Precision Surgery, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and.
J Neurosurg. 2018 Feb;128(2):380-390. doi: 10.3171/2016.10.JNS161636. Epub 2017 Apr 7.
OBJECTIVE Meningiomas are the most common primary tumor of the central nervous system. Complete resection can be curative, but intraoperative identification of dural tails and tumor remnants poses a clinical challenge. Given data from preclinical studies and previous clinical trials, the authors propose a novel method of localizing tumor tissue and identifying residual disease at the margins via preoperative systemic injection of a near-infrared (NIR) fluorescent contrast dye. This technique, what the authors call "second-window indocyanine green" (ICG), relies on the visualization of ICG approximately 24 hours after intravenous injection. METHODS Eighteen patients were prospectively identified and received 5 mg/kg of second-window ICG the day prior to surgery. An NIR camera was used to localize the tumor prior to resection and to inspect the margins following standard resection. The signal to background ratio (SBR) of the tumor to the normal brain parenchyma was measured in triplicate. Gross tumor and margin specimens were qualitatively reported with respect to fluorescence. Neuropathological diagnosis served as the reference gold standard to calculate the sensitivity and specificity of the imaging technique. RESULTS Eighteen patients harbored 15 WHO Grade I and 3 WHO Grade II meningiomas. Near-infrared visualization during surgery ranged from 18 to 28 hours (mean 23 hours) following second-window ICG infusion. Fourteen of the 18 tumors demonstrated a markedly elevated SBR of 5.6 ± 1.7 as compared with adjacent brain parenchyma. Four of the 18 patients showed an inverse pattern of NIR signal, that is, stronger in the adjacent normal brain than in the tumor (SBR 0.31 ± 0.1). The best predictor of inversion was time from injection, as the patients who were imaged earlier were more likely to demonstrate an appropriate SBR. The second-window ICG technique demonstrated a sensitivity of 96.4%, specificity of 38.9%, positive predictive value of 71.1%, and a negative predictive value of 87.5% for tumor. CONCLUSIONS Systemic injection of NIR second-window ICG the day before surgery can be used to visualize meningiomas intraoperatively. Intraoperative NIR imaging provides higher sensitivity in identifying meningiomas than the unassisted eye. In this study, 14 of the 18 patients with meningioma demonstrated a strong SBR compared with adjacent brain. In the future, reducing the time interval from dye injection to intraoperative imaging may improve fluorescence at the margins, though this approach requires further investigation. Clinical trial registration no.: NCT02280954 ( clincialtrials.gov ).
目的脑膜瘤是中枢神经系统最常见的原发性肿瘤。完全切除可以治愈,但术中识别硬脑膜尾和肿瘤残留是一个临床挑战。基于临床前研究和先前临床试验的数据,作者提出了一种通过术前静脉内注射近红外(NIR)荧光对比染料来定位肿瘤组织和识别边缘残留疾病的新方法。该技术,作者称之为“第二窗口吲哚菁绿(ICG)”,依赖于静脉注射后约 24 小时 ICG 的可视化。方法前瞻性地确定了 18 例患者,并在手术前一天接受了 5mg/kg 的第二窗口 ICG。在切除前使用近红外摄像机定位肿瘤,并在标准切除后检查边缘。测量肿瘤与正常脑实质的信号背景比(SBR)重复三次。大体肿瘤和边缘标本的荧光定性报告。神经病理学诊断作为参考金标准,计算成像技术的敏感性和特异性。结果 18 例患者中,15 例为 WHO 分级 I,3 例为 WHO 分级 II 脑膜瘤。第二窗口 ICG 输注后,手术期间近红外观察范围为 18 至 28 小时(平均 23 小时)。18 例肿瘤中有 14 例肿瘤 SBR 明显升高,为 5.6±1.7,明显高于邻近脑实质。18 例患者中有 4 例表现出近红外信号的反向模式,即正常脑旁比肿瘤强(SBR 0.31±0.1)。反转的最佳预测因子是注射后的时间,因为成像较早的患者更有可能显示出适当的 SBR。第二窗口 ICG 技术对肿瘤的敏感性为 96.4%,特异性为 38.9%,阳性预测值为 71.1%,阴性预测值为 87.5%。结论术前一天静脉内注射 NIR 第二窗口 ICG 可用于术中可视化脑膜瘤。术中近红外成像比未辅助的眼睛更能提高脑膜瘤的识别灵敏度。在这项研究中,18 例脑膜瘤患者中有 14 例与邻近脑相比 SBR 较强。在未来,减少从染料注射到术中成像的时间间隔可能会改善边缘的荧光,但这需要进一步研究。临床试验注册号:NCT02280954(clincialtrials.gov)。